INTRODUCTION
MYC was the first oncogene linked to human cancer biology and among the most deregulated genes in the cancer genome (1) . Sustained activation of the c-Myc protein upregulates a cohort of target genes involved in cell cycle, proliferation, growth, metabolism and apoptosis, which contribute to tumorigenesis in a majority of human cancers (2) . Intense research on modulation of c-Myc function has demonstrated the feasibility and benefits of c-Myc inhibition as an anti-cancer therapeutic strategy (3, 4 ).
Yet the development of an effective therapeutic approach to target c-Myc has been challenging (5) . Many attempts have been made to target c-Myc at the transcriptional level, either by inhibiting myc promoter activation (6) (7) (8) or destabilizing myc transcripts, to downregulate c-Myc. Most of these approaches have involved using anti-sense oligonucleotides and siRNA, which showed certain efficacy in inhibiting tumor growth but were often unstable and difficult to deliver in vivo (9) . Most recently, bromodomain proteins were found to regulate myc expression through a chromatin-dependent signal transduction. Inhibition of these proteins by de novo small molecules resulted in down-regulation of c-Myc expression and showed efficacy in animal multiple myeloma (10) and leukemia models (11) . This may point to a new route to target myc expression using small molecule inhibitors, yet clinical development of new drug-like molecules is often challenging. Other attempts were made to repress c-Myc activity at the protein level, either by disrupting c-Myc interaction with other factors (12, 13) or suppressing its upstream activation signaling pathway, such as MAP kinase (MAPK), to inhibit c-Myc activation.
MAPK inhibitors have shown great results in many preclinical models (14) , however most of them have failed in clinical trials, either due to lack of therapeutic efficacy, such as for PD98059 and U0126, or poor bioavailability and high toxicity, such as for CI1040 and PD0325901 (15) .
its clinical efficacy in tumor inhibition remains to be determined. To date, despite ample efforts, there have been no effective approaches to target c-Myc for cancer therapy, underscoring the continuing need for new therapeutic agents, perhaps also new approaches to accelerate development of effective c-Myc drugs.
Multimodality molecular imaging, a spectrum of imaging technologies and strategies, provides a rapid way to detect and quantify tumor response to drugs in a noninvasive and repetitive manner, and has become a key approach to accelerate drug development in both preclinical and clinical settings (18, 19) . Recent development of a c-Myc activation sensor provides a way to noninvasively monitor c-Myc activity in cells and living animals (16). This sensor is based on a split luciferase complementation system, where N-terminal and C-terminal Fig. S1 ).
In this study, we utilized the c-Myc sensor to establish a cell assay and optimized it to a high throughput-screening (HTS) format. Using this assay in a quantitative HTS (qHTS) platform, we screened about 5,000 existing bioactive compounds for potential c-Myc inhibitors. Among the most potent hits was nitazoxanide (NTZ), a human anti-protozoal drug. We further validated its inhibitory effect on c-Myc in different tumor cell lines and the efficacy of tumor inhibition in mouse xenograft models. Our HTS approach revealed for the first time the anti-c-Myc effect of NTZ and its potential role as an anti-neoplastic agent. This study also demonstrates the unique role of molecular imaging in accelerating drug development for c-Myc targeted cancer therapy.
MATERIALS AND METHODS

Chemicals and Drugs
PD98059 and U0126 were purchased from Cell Signaling. Purified Atorvastatin was purchased from Sequoia Research Products, Pangbourne, United Kingdom. The pure compound of nitazoxanide was purchased from Sigma. The 500mg tablet of nitazoxanide (Generic Alinia) was purchased from Buy-pharma.com. The purity and quantity of the drug was validated using LC-MS. D-Luciferin was purchased from BIOSYNTH.
Cell Culture and Cell Lines
All cell culture media were purchased from Invitrogen and supplemented with 10% Fetal Bovine Serum and 1% penicillin/streptomycin solution. SKBR3 (human breast adenocarcinoma) cells were cultured in McCoy's 5a medium. Osteosarcoma-derived cell line 1325 was cultured in DMEM medium. Lymphoma cells were cultured in RPMI medium supplemented with extra 3.96x10 -4 % of 2-mercaptoethanol (Sigma). All cells were incubated at 37°C with 5% CO 2 . The SK-ST and SK-FST stable cells were established by transient transfection of the sensor system or the full-length firefly luciferase genes on a single vector, and selected with 3μg/ml puromycin (Invitrogen). SKBR3 cell line was originally purchased from ATCC and passaged in house. 1325
and Lymphoma cells were provided by the laboratory of Dr. Dean Felsher from the Department of Hematology and Oncology, Stanford University. Although cell lines were not subjected to further genetic authentication, their characteristic morphologies and certain biochemical features were specifically verified. For example, overexpression of c-Myc in SKBR3 was always observed. In addition, all cell lines were tested negative for PCR evaluation for Mycoplasma pathogen using MycoAlert Kit (Lonza).
Western Blotting
Total cell lysates were collected using 1x cell lysis buffer, as directed by the manufacturer (Cell Signaling). The protein concentration was determined using the BioRad DC protein assay. SDS- PAGE analysis of 50μg of protein was transferred to Immobilon-P membrane (Millipore). Antiphospho-c-Myc (Thr58/Ser62) and anti-c-Myc antibody (Cell Signaling) were used to visualize the phospho c-Myc and c-Myc protein respectively, as directed by the manufacturer. Anti-FLuc-HRP antibody was used to detect the Firefly luciferase fragments, as directed by the manufacturer (Sigma). β-actin protein was used as loading control and detected by anti-β-actin antibody (Sigma). Immunoblots were developed using ECL kit (Pierce), as directed by the manufacturer. The protein level was determined by quantitation of the band intensities on western blots using the ROI manager of ImageJ software (Open Source).
Luciferase Activity Assay
Bioluminescence imaging of luciferase activity in intact cells was performed as described (5) .
Briefly, after indicated time of treatment, culture medium was added with PBS (pH 7.0) solution of 45μg/ml D-Luciferin for FL imaging in IVIS 50 (Xenogen). Images were acquired in 2mins interval until reaching the peak signal. The photon output of FL was normalized to the total protein of the cell lysates, measured by BioRad DC protein assay as directed by the manufacturer (Bio-rad).
Inhibition Assay
For measuring the inhibitory effect on the sensor signal, SKBR3 stable cells, constitutively expressing the sensor system (SK ST) or the full-length FL (SK FST), were treated with NTZ for 16hrs, PD98059 for 2hrs, U0126 for 1hr and Atorvastatin for 16hrs at the indicated concentration and subjected to Luciferase activity assay. For analyzing the effect on protein level, SKBR3, lymphoma and osteosarcoma cells were treated as above and lysed for western blotting of phospho c-Myc, c-Myc and β-actin proteins. The IC50 of protein inhibition was determined using non-linear regression based curve fitting and a variable model of four parameters in Prism. All treatments were repeated at least three times and the error bar indicates the plus and minus of the standard deviation from the mean of all the repeats. Hopkinton, MA, USA) to achieve 1000 fold dilution. Cells in columns 1-2 that were not treated with compounds were used as control for 100% activity. 24hrs after compound addition, the DLuc substrate was added using multi-drop liquid dispenser and imaged using the Analyst GT 
Data Analysis
Curve fitting and Student's t test were performed using Excel (Microsoft 2008) and Prism. Data are presented as described in each experimental method. Generally, for in cellulo experiments, the data point on the graph is the mean between repeated measurements, and the error bar is the standard deviation from the mean. For in vivo experiments, the data point is the mean between repeated treatment experiments and the error bar is the standard error of that mean.
P<0.05 was used as cutoff point for statistical significance.
RESULTS
Development of a HTS system using a c-Myc activation sensor based cell assay
A recent bioluminescence imaging sensor that can noninvasively detect the phosphorylationmediated activation of c-Myc ( Supplementary Fig. S1 ), provides a rapid and quantitative approach to measure c-Myc activity upon drug inhibition in an intact biological system (21) . To facilitate the drug development against c-Myc, we constructed a stable cell line constitutively expressing this c-Myc sensor, developed it into a cell assay and optimized it in a HTS format. Fig. S2C ). Since lower CV% indicates less intra-group variation, these results suggest that a cell concentration of 12,000 cells/100μl/well in a 384-well plate were optimal to achieve low signal variation between wells.
To obtain a higher signal to noise ratio, we evaluated the substrate concentration effect on the intensity and variability of the assay signal. 45mg/ml stock substrate, D-Luciferin (D-Luc), in 0.02, 0.01, 0.005, 0.002 and 0.001 dilution ratios, was added directly to each well of 12,000 cells. 0.02 (50-fold) dilution ratio, which results in 900μg/ml D-Luc, yielded the highest signal, 2.5E+05 p/s/cm 2 /sr, and the lowest CV%, 6.2% ( Fig. S3A and S3B ). Dilution ratios higher than 0.02 resulted in cell toxicity and dramatic color change of the medium. We also found, due to the kinetics of the enzyme-substrate reaction, the assay signal was unstable at the early time points after substrate addition. The average signal intensity increased and reached a plateau at 10mins after D-Luc addition and the CV% decreased from about 30% at 2mins to less than 10% at 10mins after D-Luc addition in three separate experiments ( Fig. S3C and S3D ). These results suggested that the optimal substrate concentration is 900μg/ml D-Luc and the optimal assay time is 10mins after substrate addition. To validate the quality of the assay under optimal conditions at the baseline, six 384-well plates were seeded with 12,000 cells/100μl/well in the first to the 22nd columns and 100μl medium alone in the last two columns as the blank control. The assay signal was measured ten minutes after addition of 900μg/ml D-Luc. The CV% and Z factor (22) ranged between 11.4% to 9.3% and 0.67 to 0.72 respectively (Supplementary Fig. S4 ). These data demonstrated the uniformity and robustness of the assay in a HTS format.
A quantitative HTS for inhibitors of c-Myc activation
Using the optimized sensor-based cell assay, we performed a quantitative high throughput screening against 4,846 existing bioactive compounds from five different libraries, the NIH Clinical Collection (NCC), Sigma LOPAC, Microsource Spectrum (MS), Biomol_ICB (BMI) and Biomol_FDA (BMF) (Fig. 1 ). The NCC library has over 400 drugs that have been used in clinic or clinical trials. The LOPAC library from Sigma-Aldrich has close to 1,300 compounds with proven pharmacological activities in a variety of cell signaling and neuroscience fields (23). The MS, BMI and BMF libraries have total over 3,000 compounds, which also include about 800 natural products. In a quantitative HTS platform, compounds were tested at seven different concentrations simultaneously, 0.3125, 0.625, 1.25, 2.5, 5, 10 and 20μM, except the NCC drugs, which were tested at a single concentration of 10μM. The initial hits of 337 compounds, about 10% of the total, were revealed to have a minimum of 30% inhibition at 10μM. To filter out cytotoxic agents and known luciferase inhibitors, we compared our screening results with those in the MDL Assay Explorer database, which contains dose response profiles of screenings for anti-proliferation and luciferase inhibition against the same libraries. Finally, 39 compounds, about 1% of the total, were identified as potential clean hits (Fig. 1) . These potential hits (two from the NCC library, three from the LOPAC library and 34 from the combined MS, BMI and BMF libraries) are from many compound classes ( Supplementary Fig. S5 ). The half-maximal inhibitory concentration (IC50) of the potential hits, except those from the NCC library, ranged from 1.18μM to 42.8μM ( Supplementary Fig. S6 and S7 (24, 25) . We also see drugs that are not previously described to have anti-c-Myc activity, such as nitazoxanide (NTZ), an anti-parasitic drug; 4-chloromercuribenzoic acid (pCMB), a standard cysteine protease inhibitor; and fludarabine phosphate, a purine analog acting as an antimetabolite for chemotherapy ( Supplementary Fig. S8 ). NTZ is especially interesting because it is a widely used off-label drug and well tolerated with very few side effects (26) . In this study, we chose NTZ to further validate our sensor-based HTS system.
Anti-c-Myc Efficacy of NTZ in Cell Culture
We first determined the IC50 of NTZ in vitro using the SK-ST sensor stable cells and the SK-FST firefly luciferase stable cells as a control for direct inhibitory effect on luciferase activity.
NTZ induced dose dependent reduction of sensor signals in SK-ST cells after 16hrs treatment, while no significant changes occurred in SK-FST cells ( Fig. 2A and 2B ). The IC50 for the sensor signal inhibition of NTZ was about 100nM, which was about 2000-and 500-fold lower than that of c-Myc upstream kinase inhibitors, PD98059 and U0126 (2) respectively ( Fig. 2C and 2D) ; and about 50-fold lower than that for a HMG-coA inhibitor, Atorvastatin (AT), which was recently found to be a potent c-Myc inhibitor (3, 21) . Moreover, NTZ indeed induced dose dependent reduction of the endogenous phospho c-Myc and c-Myc proteins and the IC50 was consistent with that for the sensor signal (Fig. 3A) . To examine the inhibitory spectrum of NTZ, we also tested its efficacy in other c-Myc associated tumor cell lines, lymphoma and osteosarcoma cells. Fig. S10) , which was about 10-fold higher than its IC50. This wide range between LD50 and IC50 implies a safe therapeutic effect of NTZ. 
Anti-tumor efficacy of NTZ in mouse tumor models
To determine whether NTZ could affect tumor growth as a single agent in vivo, we tested it in two tumor xenograft models. In one model, SK-ST cells were implanted subcutaneously into nude mice (N=12, Fig. 4A ) to monitor the effect of NTZ on c-Myc activation, and in the other model, SK-FST cells were implanted (N=12, Fig. S11 ) to monitor cell numbers and the direct drug effect on FL activity. Since there has not been any in vivo study on effective dosage of NTZ in treating tumors, we chose a dose commonly used in animal models of protozoan infection that induces maximum growth inhibition without significant side effects (27, 28) . Three days after implantation, mice were gavaged with NTZ (200mg/kg, N=6) in 100μl 0.5% CMC suspension or with the same volume of 0.5% CMC solution (N=6) twice a day for 27 days. The same regimen was repeated three times for each model. We found that the bioluminescent signal from SK-ST xenografts increased rapidly 10 days after implantation in the CMC group, but is greatly inhibited in the NTZ group (Fig. 4A and 4B ). The signal of SK-FST xenografts slowly increased in both groups at the start, and about 18 days after implantation significant increase (P<0.05) of the signal was seen in the CMC group while sustained decrease of the signal was seen in the NTZ group (Supplementary Fig. S11 ). This signal change was consistent with the change in tumor size, where 18 days after implantation the average tumor size of the CMC group was significantly larger (P<0.001) than that of the NTZ group (Fig. 5) . Twenty-seven days after implantation in a SK-ST xenograft model, we dissected out tumors from each group and observed drastic inhibition of tumor growth in the NTZ group by gross inspection and caliper measurements (P=0.00007) (Fig. 5A and 5B). H&E and Ki67 staining of the tumor samples indicated similar histology and cell proliferation pattern in the CMC and NTZ groups. However, the caspase-3 staining in the NTZ group gave average 23±8 positive cells in each sample (Fig.   6A ), which is significantly greater than the average 5±2 positive cells in the CMC group (P<0.03). This indicates that there is a significant increase of apoptosis in the NTZ treated group. The endogenous phospho and c-Myc protein levels were also greatly reduced in the tumor samples from the NTZ group as compared with the CMC group (Fig. 6B) regimen, we didn't observe the common side effects of NTZ in animal models of protozoan infection, such as diarrhea, vomiting and skin rash (7, 10) . However, the mice had a 7-10% body weight loss in the NTZ group but not in the CMC group 12 days after implantation ( Supplementary Fig. S12 ). This weight loss can be reversed upon removal of the NTZ treatment. Together, these results demonstrated an in vivo efficacy of NTZ in inhibiting c-Myc activity and tumor growth. compound screening against c-Myc, we further developed this reporter system into a robust cell-based assay and optimized it in a HTS platform ( Supplementary Fig. S1-4 ). This new HTS system enables large-scale screening for compounds that regulate c-Myc activation in live cells.
DISCUSSION
Furthermore, since the sensor-based assay measures changes at the level of the protein itself, it can capture upstream effects on c-Myc from both immediate and multi-level cross interactions.
Therefore the targets of the resulted hits can be direct or indirect regulators of c-Myc activation.
Although further low-throughput biological assays are needed to examine the c-Myc activation induced downstream effect, this system screens for upstream effectors and tends to identify more potent agents that potentially impact many downstream pathways of c-Myc rather than look for downstream effectors that only involve in a single or a few pathways.
We applied this new screening system on a quantitative HTS (qHTS) platform and screened against five different libraries of total about 5,000 compounds with known bioactivities. The qHTS platform allows compounds to be tested simultaneously in seven different concentrations.
It not only facilitates rapid fitting and classification of the concentration-response curves for identification of compounds with a variety of potencies and efficacies, but also is more reliable than traditional single-concentration HTS due to the lower prevalence of false negative hits (30) .
Not surprisingly, among all the clean hits anti-neoplastic compounds are the most frequently occurred. Interestingly, the second most frequently occurred are anti-parasitic and anti-bacterial compounds ( Supplementary Fig. S5 ). NTZ, one of the anti-parasitic drugs, was among the top potent hits (Supplementary Fig. S6 ).
NTZ is a thiazolide (Fig. 2C) anaerobic bacteria (32) . The salicylic acid moiety, on the other hand, is responsible for the activities against intracellular parasites by interacting with thiazolide-binding proteins. More recent studies in other pathogens indicate that NTZ has a broad-spectrum of activity by interfering in various signaling pathways. Studies in HCV suggested that NTZ exhibits anti-viral activity by inducing PKR (protein kinase activated by double-stranded RNA) mediated phosphorylation of eIF2α that enhances host cell antiviral defenses (33) . A study in Mycobacteria tuberculosis (Mtb) suggests that NTZ inhibits mTORC1 signaling pathway (34), which is known to regulate c-Myc activity. Another study in mouse macrophages showed inhibitory activity of NTZ against IL-6 production (35). Although there was no reported in vivo study on anti-neoplastic activity of NTZ, an in vitro study in human colon cancer cells suggested that NTZ inhibits tumor cell growth by interaction with glutathione-S-transferase P1 (GSTP1) (36) . Interestingly, colon cancer has the highest myc over-expression among all human cancers (GenAtlas.org) and GSTP1 interferes the kinase activity of MAPK8 (37), which is an upstream regulator of c-Myc. Thus, the growth inhibition by NTZ in colon cancer cells could be a downstream effect of c-Myc inhibition. Our study, for the first time, revealed a potent efficacy of NTZ in c-Myc inhibition both in tumor cell lines and mouse tumor xenograft models.
To further explore the molecular mechanism of NTZ's inhibitory effect on c-Myc, we first checked ChEMBL, a comprehensive bioactivity database for medicinal chemicals, and collected all experimentally identified NTZ targets. There are total 30 different human targets of NTZ, including MAPK1/ERK and TP53/P53 (Supplementary Fig. S13 ). ERK is the immediate upstream kinase of c-Myc, which phosphorylates and activates c-Myc, while the tumor suppressor protein P53 is often suppressed when c-Myc is activated. These in vitro data suggest potential pathways that NTZ acts on to inhibit c-Myc activation. Since both ERK and TP53 act upstream of c-Myc activation, these data also provide validation for our screening strategy for upstream inhibitors of c-Myc. Alternatively, we found another anti-parasitic family member, pyrvinium, has similar anti-neoplastic effect. It was shown that pyrvinium inhibits the cell growth of human colon cancer (38) . Casien kinase 1 alpha (CK1α) was identified as the Supplementary Fig. S13 ).
The wide spectrum of NTZ targets implies the complexity of its action. NTZ is supposed to bind its target to exert its function inside cells. Further to its wide spectrum of activity, NTZ is extremely well tolerated. It was the first antiparasitic compound developed for human use back in the mid-1990s (42) and is the only antiprotozoal drug approved for use in children. Indeed, there was a wide range between LD50 and EC50 of NTZ in SKBR3 breast cancer cells (Fig. 3 and Supplementary Fig. S10 ). The ratio between LD50 and IC50 is often referred as the therapeutic index of the drug (43) mechanism of anti-viral activity (44) . These trials provided valuable information about effective regimens that cannot be obtained in preclinical experiments. For example, the realization that a 4-week lead-in of NTZ monotherapy followed by combination therapy with a current anti-HCV agent provides sustained anti-viral efficacy (45). The combination approach in anti-viral therapy hints at the possible application of NTZ in anti-neoplastic therapy. In fact, most of the top hits from our screen were anti-neoplastic agents (Fig. S4) , such as fludarabine phosphate (F-ara-A) ( Supplementary Fig. S8 ) currently used for chronic lymphocytic leukemia (CLL). While it is interesting to figure out how a DNA analog has anti-c-Myc activity, it remains potentially of benefit to know whether combining F-ara-A and NTZ could improve clinical outcome of CLL.
Here we developed a new molecular imaging based quantitative high throughput screening approach. By utilizing it, we identified an anti-c-Myc effect of NTZ and validated its efficacy in both tumor cell lines and mouse xenograft models. Our study provides evidence for a potential new spectrum of clinical applications of NTZ. Moreover, the molecular imaging strategy coupled with systematic profiling of compound libraries promises to accelerate identification of new therapeutic agents or re-purposing of known drugs, as well as their in vivo validation in preclinical models of disease.
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